Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer – the MetAction precision medicine study

References

• Tannock IF, Hickman JA. Molecular screening to select therapy for advanced cancer? Ann Oncol. 2019;30(5):661–663.
   PubMed Web of Science ®Google Scholar
• Ree AH, Russnes HG, Heinrich D, et al. Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. ESMO Open. 2017;2(2):e000158.
   PubMed Web of Science ®Google Scholar
• Weymann D, Pataky R, Regier DA. Economic evaluations of next-generation precision oncology: a critical review. JCO Precis Oncol. 2018;2:1–23.
   PubMed Web of Science ®Google Scholar
• Kasztura M, Richard A, Bempong N-E, et al. Cost-effectiveness of precision medicine: a scoping review. Int J Public Health. 2019;64(9):1261–1271.
   PubMed Web of Science ®Google Scholar
• Chan KKW, Tannock IF. Should basket trials be pathways to drug registration for biomarker-defined subgroups of advanced cancers? J Clin Oncol. 2021;39(22):2426–2429.
   PubMed Web of Science ®Google Scholar
• Ree AH, Nygaard V, Boye K, et al. Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer – the MetAction study. Acta Oncol. 2020;59(7):733–740.
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–1919.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.
   PubMed Web of Science ®Google Scholar
• Guidelines for the submission of documentation for single technology assessment (STA) of pharmaceuticals. [cited 2021 Dec 20]. Available from: https://legemiddelverket.no/Documents/English/Public%20funding%20and%20pricing/Documentation%20for%20STA/Guidelines%2020.05.2020.pdf.
   Google Scholar
• Färkkilä N, Torvinen S, Sintonen H, et al. Costs of colorectal cancer in different states of the disease. Acta Oncol. 2015;54(4):454–462.
   PubMed Web of Science ®Google Scholar
• Ratcliffe J, Longworth L, Young T, et al. Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl. 2002;8(3):263–270.
   PubMed Web of Science ®Google Scholar
• Bjørnelv GMW, Dueland S, Line P-D, et al. Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver. Br J Surg. 2019;106(1):132–141.
   PubMed Web of Science ®Google Scholar
• WebPlotDigitizer. [cited 2021 Dec 20]. Available from: https://automeris.io/WebPlotDigitizer/.
   Google Scholar
• Latimer NR. Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743–754.
   PubMed Web of Science ®Google Scholar
• Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19(6):716–723.
   Web of Science ®Google Scholar
• Schwarz G. Estimating the dimension of a model. Ann Statistics. 1978;6:461–464.
   Web of Science ®Google Scholar
• Bjørnelv GMW, Edwin B, Fretland ÅA, et al. Till death do us part: the effect of marital status on health care utilization and costs at end-of-life. A register study on all colorectal cancer decedents in Norway between 2009 and 2013. BMC Health Serv Res. 2020;20(1):115.
   PubMed Web of Science ®Google Scholar
• Barton GR, Briggs AH, Fenwick EAL. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health. 2008;11(5):886–897.
   PubMed Web of Science ®Google Scholar
• Ree AH, Nygaard V, Russnes HG, et al. Responsiveness to PD-1 blockade in end-stage colon cancer with gene locus 9p24.1 copy-number gain. Cancer Immunol Res. 2019;7(5):701–706.
   PubMed Web of Science ®Google Scholar
• Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 2018;4(8):1093–1098.
   PubMed Web of Science ®Google Scholar
• Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491–1505.
   PubMed Web of Science ®Google Scholar
• Cutler DM. Early returns from the era of precision medicine. JAMA. 2020;323(2):109–110.
   PubMed Web of Science ®Google Scholar
• Vokinger KN, Hwang TJ, Grischott T, et al. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol. 2020;21(5):664–670.
   PubMed Web of Science ®Google Scholar
• Kouakou CRC, Poder TG. Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression. Eur J Health Econ. 2022;23(2):277–299.
   PubMed Web of Science ®Google Scholar
• Cooper K, Tappenden P, Cantrell A, et al. A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer. Br J Cancer. 2020;123(11):1686–1696.
   PubMed Web of Science ®Google Scholar
• Fleck LM. Precision medicine and the fragmentation of solidarity (and justice). Med Health Care Philos. 2022;25(2):191–206.
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Fojo T, Chamberlain C, et al. Do patient access schemes for high-cost cancer drugs deliver value to society?–lessons from the NHS Cancer Drugs Fund. Ann Oncol. 2017;28(8):1738–1750.
   PubMed Web of Science ®Google Scholar
• Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35(13):1453–1486.
   PubMed Web of Science ®Google Scholar
• Martini G, Dienstmann R, Ros J, et al. Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. Ther Adv Med Oncol. 2020;12:1758835920936089.
   Web of Science ®Google Scholar
• van der Velden DL, Hoes LR, van der Wijngaart H, et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019;574(7776):127–131.
   PubMed Web of Science ®Google Scholar
• van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, et al. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. Ann Oncol. 2019;30(5):663–665.
   PubMed Web of Science ®Google Scholar
• Taskén K, Russnes HEG, Aas E, et al. A national precision cancer medicine implementation initiative for Norway. Nat Med. 2022;28(5):885–887.
   PubMed Web of Science ®Google Scholar